Abnormal AI Named to CNBC Disruptor 50 List for Second Consecutive Year, Showcasing Continued Innovation and Leadership in AI-Powered Cybersecurity
Abnormal AI was selected for its significant business growth and transformative product ecosystem. The annual list is curated by CNBC's editorial team with input from data partners PitchBook and IBISWorld, and the Disruptor 50 Advisory Council, composed of experts in innovation and entrepreneurship who evaluate companies based on a blend of quantitative and qualitative insights. This award acknowledges how Abnormal is leveraging bold ideas, cutting-edge technologies, and scalable models to challenge incumbents and drive real-world impact.
'It's an incredible honor to be recognized as a CNBC Disruptor once again,' said Evan Reiser, CEO and founder of Abnormal AI. 'Earning this accolade for the second consecutive year validates our relentless focus on innovation, our commitment to our customers, and our continued creation of breakthrough technology that's reshaping the future of cybersecurity through the power of behavioral AI.'
Since its founding in 2018, Abnormal AI has emerged as a category leader, protecting over 3,200 organizations, including more than 20% of the Fortune 500, with unparalleled speed and accuracy. Its behavioral AI platform has mitigated over $10 billion in annual risk, with adoption accelerating globally. The company has continued its strong trajectory by continuing to hit landmark milestones—launching breakthrough AI agents that reimagine security awareness training, achieving FedRAMP authorization in just 256 days, and announcing plans to expand into new countries across Europe and Asia.
In addition to this back-to-back CNBC Disruptor 50 recognition, Abnormal has also been honored with several other accolades in recent months. A few of these distinctions include placement Fortune's Most Innovative Companies of 2025, making the CRN AI 100 as a top 20 hottest AI cybersecurity company for the second consecutive year, winning two 2025 Cyber Defense Magazine Global Infosec Awards for Cutting Edge Cybersecurity AI and Pioneering Email Security and Management, as well as securing spots on the Rising in Cyber 2025, SC Awards Europe (for Best Email Security Solution and Best Behavior Analytics/ Enterprise Threat Detection), and 2025 InfraRed 100.
Michael DeCesare, president at Abnormal AI added, 'This recognition on the CNBC Disruptor 50 reinforces the traction that we are seeing in the market as appetite grows for AI-native solutions. Our go-to-market strategy is accelerating alongside this rising demand, especially as organizations across industries face escalating threats—including those powered by AI. We're turning the tables: using good AI to fight malicious AI.'
For the full CNBC Disruptor 50 list, visit here.
About Abnormal AI
Abnormal AI is the leading AI-native human behavior security platform, leveraging machine learning to stop sophisticated inbound attacks and detect compromised accounts across email and connected applications. The anomaly detection engine leverages identity and context to understand human behavior and analyze the risk of every cloud email event—detecting and stopping sophisticated, socially-engineered attacks that target the human vulnerability.
You can deploy Abnormal in minutes with an API integration for Microsoft 365 or Google Workspace and experience the full value of the platform instantly. Additional protection is available for Slack, Workday, ServiceNow, Zoom, and multiple other cloud applications. Abnormal is currently trusted by more than 3,200 organizations, including over 20% of the Fortune 500, as it continues to redefine how cybersecurity works in the age of AI. Learn more at abnormal.ai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 minutes ago
- Business Wire
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into securities purchase agreements with several institutional and accredited investors (the "Purchasers") for the purchase and sale of 990 shares of the Company's Series B Convertible Preferred Stock (the 'Preferred Stock') and warrants (the 'Private Placement Warrants') to purchase approximately 6.7 million shares of common stock (the 'Private Placement'). The Company shall use the net proceeds from the Private Placement and Warrant Inducement for working capital and general corporate purposes. The shares of Preferred Stock have a stated value of $1,000 per share and are initially convertible into an aggregate of approximately 4.3 million shares of common stock at a conversion price of $0.23 per share. The Private Placement Warrants will be exercisable following the date on which the Company obtains stockholder approval of the exercise thereof at an initial exercise price of $0.352 per share and expire five years from the original exercise date. The Company also announced today it has entered into a warrant exercise agreement with an existing accredited investor to exercise (i) outstanding warrants to purchase 450,000 shares of the Company's shares of common stock that were issued in August 2024 (the 'August Warrants') and (ii) outstanding warrants to purchase 650,000 shares of the Company's common stock that were issued in October 2024 (the 'October Warrants' and together with the August Warrants, the 'Existing Warrants'), which reduced the exercise prices of the August Warrants from $1.50 to $0.23 per share and the October Warrants from $1.25 to $0.23 per share and provided for the issuance to such investor of new unregistered warrants (the 'New Warrants') to purchase up to an aggregate of 1.43 million shares of the Company's common stock in consideration for the immediate exercise in full of the Existing Warrants for gross cash proceeds to the Company of approximately $253,000 (the 'Warrant Inducement'). The New Warrants will have an exercise price of $0.352 per share and will be initially exercisable on the date that stockholder approval of the exercise of the New Warrants is obtained and will expire five years from the date of such approval. The closing of the Private Placement and Warrant Inducement is expected to occur on or about August 14, 2025, subject to the satisfaction of customary closing conditions. The expected aggregate proceeds (before expenses) of the Private Placement and Warrant Inducement will be approximately $1.2 million. The Company shall use the net proceeds from the Private Placement and Warrant Inducement for working capital and general corporate purposes. WallachBeth Capital LLC is acting as the sole placement agent for the Private Placement and financial advisor for the Warrant Inducement. The securities described above will be offered in a private placement exempt from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act") and Regulation D promulgated thereunder and in a transaction not involving a public offering and have not been registered under the Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock underlying the Preferred Stock, the Private Placement Warrants and New Warrants within 15 calendar days after the closing date. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About CyPath® Lung CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the closing of the offering on August 14, 2025. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to close the offering when anticipated and the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Business Wire
17 minutes ago
- Business Wire
Alen Celebrates 20 Years of Innovation and Leadership in Air Purification For Home, School and Work
AUSTIN, Texas--(BUSINESS WIRE)-- Alen, a leader in the air purification industry, today celebrates 20 years of creating best-in-class air purifiers that ensure the health and safety for millions of Americans. The Austin-based company has become a trusted name in clean air solutions since its founding in 2005, recognized by leading industry and scientific experts for its powerful technology, thoughtful design and its deep commitment to healthier living. 'Alen began with one goal in mind. Make clean air simple, effective, and accessible, for people and pets,' said Warburg Lee, Founder and CEO of Alen. 'Since then, both outdoor and indoor air quality have worsened due to wildfires, increased allergens, and viruses, making our mission even more critical. We're a health and wellness company, not just an air purifier company, with a mandate to create healthy living and working environments. From our earliest models to our most recent advanced purifier models, our north star is that we remove 99.9 percent of airborne particulates while operating quietly in the background to protect what matters most.' 20 years of achievements include: Growing from start-up to nationally recognized brand with over 50 team members, availability in all 50 states, serving more than 2 million customers worldwide, and developing the fifth generation of advanced air purifier systems with new products launching in October 2025. Meeting critical third-party standards, including certifications from ENERGY STAR, Quiet Mark, SleepScore Labs, and the Asthma and Allergy Friendly Program. Products are tested to remove up to 99.9 percent of airborne particles down to 0.1 microns. Sought-after by national retailers including Lowe's and Amazon to carry Alen products because they are a trusted brand for homes, schools, and businesses across the country. Continued excellence in technology, developing proprietary technology, industry-first features, and responsive design with intelligent sensors and proprietary airID technology that detects and responds to real-time air quality changes, automatically adjusting to remove pollutants like dust, smoke, and chemicals for cleaner, healthier air. Day-one pursuit of design to fit the aesthetics of modern living. Alen purifiers blend seamlessly into bedrooms, offices, classrooms, and large commercial spaces with multiple sizes, ultra-quiet performance, and customizable designer panels. Alen's mission to improve indoor air became a national movement for wellness. Alen continues to lead with purpose, innovation, and a long-standing commitment to help people breathe better and live healthier. Alen is preparing to introduce new models later this year, building on its reputation for premium air purification and breakthrough technology. These upcoming releases will reinforce its position as a leader in clean air solutions. Alen is poised to deliver greater impact across both retail and business-to-business markets, backed by ongoing innovation, supply chain strength, and strategic commercial partnerships. To explore Alen's full range of air purification solutions, visit About Alen Alen is an Austin-based innovator of high-performance air purifiers, committed to creating healthier indoor environments through advanced, scientifically validated technology. Alen's purifiers use True HEPA filters and are independently certified by Quiet Mark, the Asthma & Allergy Friendly® Certification Program, SleepScore Labs, and ENERGY STAR® for delivering best-in-class air purification, energy efficiency, ultra-quiet operation, and improved sleep quality. Alen's mission to enhance quality of life in homes, workplaces, and shared spaces is driven by the belief that wellness begins with pure air. Alen empowers individuals and families to lead healthier lives with cleaner, safer air and greater peace of mind through proprietary features like airID smart sensor technology and a commitment to lifetime reliability.
Business Wire
17 minutes ago
- Business Wire
BM3EAC Corp. 2025 Semi-Annual Report
AMSTERDAM--(BUSINESS WIRE)--BM3EAC Corp. (the 'Company'), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2025 to 30 June 2025. The semi-annual report can be downloaded from the Company's website via the following link: This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER The Company's semi-annual report referenced in this announcement may include forward-looking statements, which are based on the Company's current expectations and projections regarding a business combination, the business, the economy and other future conditions of the Company and speak only as of the date hereof. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Company's business, results of operations, financial position, liquidity, prospects, growth or strategies. The Company shall have no obligation to update any forward-looking statements after the date of this announcement. This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does not contain or constitute an offer of securities for sale or an invitation or offer to the public for securities in any jurisdiction. In the EEA, this announcement is only directed at persons who are 'qualified investors' within the meaning of Article 2(e) of the Prospectus Regulation (EU 2017/1129) as amended. In the United Kingdom, this announcement is directed only at 'qualified investors' within the meaning of Article 2(e) of the Prospectus Regulation (EU) No 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.
